The AI in Drug Discovery Market is expanding globally as pharmaceutical companies, biotechnology firms, and research organizations adopt artificial intelligence for advanced drug development activities. Market Research Future projects the market to increase from USD 2.81 billion in 2025 to USD 23.95 billion by 2035, at a CAGR of 23.9%.

North America currently represents the largest regional market. Strong pharmaceutical and biotechnology ecosystems, significant research investment, advanced computing infrastructure, and a high concentration of AI companies support regional adoption. The United States is particularly important because of its established pharmaceutical research environment and technology ecosystem.

Europe represents another significant market, supported by pharmaceutical research capabilities, biotechnology innovation, and increasing adoption of artificial intelligence in healthcare. Organizations across the region are exploring AI for drug discovery, clinical research, and biomedical data analysis.

Asia-Pacific is expected to be the fastest-growing regional market. Increasing pharmaceutical investment, expanding biotechnology sectors, government support for artificial intelligence, and growing research capabilities in countries such as China, India, and Japan are contributing to regional opportunities. Market Research Future estimates Asia-Pacific to grow at approximately 27.4% CAGR during the forecast period.

South America and the Middle East and Africa are also expected to develop as healthcare technology adoption increases.

Looking ahead, regional growth will be supported by cloud computing, AI research funding, strategic partnerships, improved data infrastructure, and increasing demand for faster drug development. Emerging markets may provide significant opportunities for AI platform providers as pharmaceutical and biotechnology capabilities expand.